Cystagon®

DRUG2 trials

Sponsors

Amgen

Conditions

Cystinosis

Phase 1

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

CompletedNCT00872729

AmgenCystinosis

Start: 2009-05-31End: 2009-10-31Updated: 2024-12-19

Phase 3

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

CompletedNCT01733316

AmgenCystinosis

Start: 2013-01-31End: 2017-07-10Updated: 2024-12-27